Mineralys Therapeutics (MLYS) Cash & Equivalents (2022 - 2026)

Mineralys Therapeutics has disclosed Cash & Equivalents across 5 years of filings, most recently posting $111.6 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $111.6 million, down 32.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $111.6 million (down 32.35% YoY), and the FY2025 annual result was $171.9 million, up 50.66% from the prior year.
• Cash & Equivalents came in at $111.6 million for Q1 2026 at Mineralys Therapeutics, down from $171.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $216.4 million in Q3 2025 to a low of $49.3 million in Q4 2023.
• The 5-year median for Cash & Equivalents is $101.0 million (2023), against an average of $113.6 million.
• Across the five-year window, Cash & Equivalents sank 41.88% in 2023 and jumped 131.4% in 2024, its largest moves.
• Mineralys Therapeutics' Cash & Equivalents stood at $84.8 million in 2022, then tumbled by 41.88% to $49.3 million in 2023, then surged by 131.4% to $114.1 million in 2024, then surged by 50.66% to $171.9 million in 2025, then tumbled by 35.06% to $111.6 million in 2026.
• The last three Cash & Equivalents figures came in at $111.6 million (Q1 2026), $171.9 million (Q4 2025), and $216.4 million (Q3 2025), per Business Quant data.